AGGF1 and idiopathic pulmonary fibrosis: We also show that IPF treatment agent pirfenidone attenuates TAC-induced arterial dilatation, inflammation and remodeling by inhibiting Smad3 activation and ERK1/2 activation, and this effect is dependent on AGGF1.